Clinical trial
Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced…
NCT02702414 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT02702414 |
|---|---|
| Title | Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224) |
| Official title | A Phase 2 Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects With Advanced Hepatocellular Carcinoma (KEYNOTE-224) |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hepatocellular Carcinoma |
| Intervention type | Biological |
| Interventions | Pembrolizumab |
| Enrollment | 156 |
| Start date | May 31, 2016 |
| Primary completion | Jan 19, 2021 |
| Completion | Sep 29, 2023 |
| First posted | Mar 8, 2016 |
| Last update posted | Sep 4, 2024 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: